{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-035911","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2026-11-09T21:32:22+00:00","discovered_at":"2026-11-09T21:33:00.252472+00:00","generated_at":"2026-11-09T21:33:04.712035+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GeoVax names Tyler O'Brien interim CEO and chairman; five directors resigned, Behroyan joins board","bullets":["Tyler O'Brien appointed interim Chief Executive Officer effective Nov 8, 2026, also named Chairman of the Board, serving as principal executive officer until a permanent CEO is named.","Shahin Behroyan, 39, appointed a director Nov 5, 2026; he has been CEO of iSpecimen (Nasdaq: ISPC) since Aug 26, 2026 and is deemed independent under Nasdaq Rule 5605(a)(2).","Behroyan fills a board vacancy created by the resignation of five former directors effective Oct 23, 2026; he has no immediate committee assignment.","Filing discloses Mr. Dodd's employment was terminated for 'Cause,' with potential severance of 3x base salary plus target bonus and accelerated stock option vesting if disputed.","Company cites risks including Dodd litigation, going-concern doubt, and the need to regain and maintain Nasdaq continued listing compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-035911","json":"https://secwatch.observer/filing/0001437749-26-035911.json","markdown":"https://secwatch.observer/filing/0001437749-26-035911.md","text":"https://secwatch.observer/filing/0001437749-26-035911.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774926035911/0001437749-26-035911-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774926035911/govx20261109_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-09T21:33:04.712035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"322012c080","claim":"Shahin Behroyan was appointed as director at GeoVax Labs, Inc..","evidence_excerpt":"Effective November 5, 2026, the Board of Directors appointed Shahin Behroyan as a director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774926035911/0001437749-26-035911-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"398a9df612","claim":"Tyler O’Brien was appointed as interim Chief Executive Officer at GeoVax Labs, Inc..","evidence_excerpt":"Effective November 8, 2026, the Board of Directors appointed Tyler O’Brien as interim Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774926035911/0001437749-26-035911-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"4759ea999d","claim":"Tyler O’Brien was appointed as Chairman of the Board at GeoVax Labs, Inc..","evidence_excerpt":"Effective November 8, 2026, Mr. O’Brien was also appointed as Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774926035911/0001437749-26-035911-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}